Cancer Service Guidance on Improving Outcomes for People with Sarcoma is being developed for use in the NHS in England and Wales. Registered stakeholders for the Improving Outcomes for People with Sarcoma Cancer Service Guidance are invited to comment on the provisional guidance recommendations via this website.

Although individuals and organisations not registered as stakeholders are able to comment, we recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. We work closely with stakeholder organisations and take their views very seriously.

• List of registered stakeholders and information on the progress for this guideline topic ? click here

Note that the provisional guidance recommendations presented here do not constitute the Institute's formal guidance on this guidance topic. The recommendations are provisional and may change after consultation.

CONSULTATION DATES:  9 May 2005 ? 6 June 2005

Consultation documents:

• Full guidance
• Comments proforma

The full version describes the evidence and views that have been considered, and sets out the provisional guidance recommendations that have been developed. It is important that you read this first to understand the background to the recommendations.

Points to consider in the first consultation:

Full version

• points or areas that are not covered, but which appear to fall within the scope of the guidance
• potential inconsistencies or any disagreement with the Guidance Development Group?s interpretation of the evidence
• the practical value of the provisional guidance recommendations.

A second version of this guidance ? Information for the Public ? is yet to be developed, and will be available for comment in the 2^nd round.

How to submit your comments:

Please use the comments proforma above and return by email to sarcoma@nice.org.uk or on a disk to:

Cathryn Fuller
Guidelines Coordinator
National Institute for Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

The Institute is unable to accept and will not respond to:

• Comments on the scope.  The scope has been finalised
• Comments on the guidance that fall outside of the remit and the scope
• More than one response per stakeholder organisation
• Comments received after the consultation deadline
• Comments that are not on the correct proforma
• Confidential information or other material that you would not wish to be made public
• Personal medical information about yourself or another person from which your or the person?s identity could be ascertained.

What will happen to your comments:

• All comments (with the exception of personal, individual comments) will be sent to the developers at the end of the consultation
• Comment from registered stakeholders ONLY will be formally responded to by the developers and posted on the NICE website after the final guidance is published
• Personal, individual comments will be forwarded to the Patient Involvement Unit for NICE, who will consider them when making their response.

Acknowledgement of comments:

You should receive an automated acknowledgement from the email box when you email your comments.  If you do not receive this acknowledgement, please contact the relevant Guidelines Coordinator to ensure they have been safely received.

2^nd round consultation dates:  30 August 2005 ? 27 September 2005

Anticipated publication date:    March 2006

WEBSITE LINKS

• We have answered some frequently asked questions on our clinical guidelines ? click here
• For more information on NICE?s guideline development process - click here